Continued sorafenib treatment inhibits tumor angiogenesis, resulting in a hypoxic environment within the tumor and facilitating the selection of resistant cell clones that attempt to adapt to oxygen and nutrient deprivation, leading to sorafenib resistance via the activation of HIF-1α and NF-κB in HCC [179]. Here, NFKB1 is linked to hepatocellular carcinoma.